Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 13 November 2025 2025 Annual General Meeting Melbourne, Australia; 13 November 2025: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release a copy of the Chair’s address and Managing Director’s presentation, which will be delivered at the Company’s Annual General Meeting today. These documents will also be available on the Company’s InvestorHub portal, which enables shareholders, stakeholders, prospective investors and partners to learn more about the Company's activitiesand key projects. TheCompany regularly uploadsnew content to the hub,including videos, key project news and updates. Shareholders and interested parties can join InvestorHub via the “sign up” button on the Company’s website (www.cynata.com). -ENDS- Authorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com Chair’s Address to Shareholders 2025 Annual General Meeting It is my pleasure to address you all today at Cynata’s Annual General Meeting. Following my address, I will invite Kilian and his senior management team to provide an update on the Company’s progress and outlook, including the major clinical trial readouts expected in the current financial year. I ask that any questions relating to the Company’s operations be held until the team has completed the presentation. Key highlights for the 2025 financial year include: • We completed the Phase 1 clinical trial in diabetic foot ulcers, with very positive results. Our novel wound product was safe and well tolerated, and showed substantially improved wound healing compared to the standard of care control group. • Significant progress was made in the enrolment of patients in the Phase 2 graft versus host disease clinical trial, with completion of enrolment now expected imminently. • The final patients in our Phase 3 osteoarthritis clinical trial, in partnership with the University of Sydney, completed study treatment, with completion of final patient follow-up visits expected this month. • Our partners at Leiden University Medical Center in the Netherlands completed treatment of the first cohort of patients in the Phase 1/2 kidney transplant trial, with DSMB review results expected shortly. We also continued to build on our preclinical data, with encouraging data in models of pulmonary fibrosis and ischaemic heart disease, supporting potential expansion into large additional markets. Additionally, an important scientific paper underlining strengths of our Cymerus™ platform relative to conventional manufacturing methods was published in a leading peer-reviewed journal. Without question, we are now entering the most important chapter in the Company’s history, with results of two randomised controlled efficacy trials expected this financial year. These results have the potential to transform the Company, and set us on a new commercial trajectory with a valuation to reflect that. On behalf of the Board, I would like to acknowledge my fellow directors and our staff, and recognise the contribution that each of them has made to our Company. I would also like to thank all of our shareholders for their ongoing support. I would now like to pass on to Kilian and team to provide a more detailed overview of the Company’s progress, and the outlook for the year ahead. 1 cynata.com MD’s Presentation Dr Kilian Kelly CEO & MD Important Information Summary information This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (CYP, or Cynata) which is current as at 12 November 2025. This Presentation should be read in conjunction with CYP’s other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. Not an offer This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distributionof this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment advice This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities. Investment risk and past performance An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance. Financial data All financial information in this Presentation is in Australian currency (A$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding. Forward-looking statements This Presentation contains certain ‘forward looking statements’, which can generally be identified by the use of forward looking words such as ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties andother factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements. Industry and Market data Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications. Disclaimer To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (Related Persons) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. cynata.com 2 Cynata Snapshot Next-generation Mesenchymal Stromal Cells (MSCs)1 Who we are Who we are Commercialising CymerusTM, a novel platform producing consistent and potent MSCs from a single blood donation - once, at scale. What are MSCs? Industry Barrier Our Advantage MSCs are powerful immune-modulating and tissue-repairing cells, but naturally scarce in the human body. Traditional manufacturing relies on continuously finding donors and faces inconsistency, potency loss, and scaling limits. Cynata solves the MSC production bottleneck, unlocking full therapeutic and commercial potential. cynata.com 1. Also known as Mesenchymal Stem Cells 3 Capital Structure Strong balance sheet. Positioned for upside. 4 cynata.com Backed by institutions: Fidelity, BioScience Managers, and Fujifilm among top holders Funded through milestones: Cash runway secured to mid-2026 - through landmark clinical readouts Attractive valuation: Current market cap does not reflect value of advanced clinical pipeline and near-term catalysts Tightly held register: Top 20 own ~45% Share price (12 November 2025) A$0.25 Shares on issue ~237.5m Market capitalisation ~A$59m Cash1 ~ A$4.9m 1 - As of 30 September 2025; based on cash balance at end of quarter of ~$3.2m plus R&D Tax Incentive rebate of ~$1.7m received on 5 November 2025 Financial Information Top Holders 9.9% 8.2% 3.4% Cynata Is At An cynata.com Tightly focused clinical pipeline Advancing four clinical programs to address critical treatment gaps Company- (and industry-) defining data readouts this financial year Manufacturing process established and ready to scale Positioned well for global licensing and joint venture deals Inflection Point Phase 1 Market Size Phase 2 Phase 3 Next Catalyst* US$11.6bn3 Osteoarthritis CYP-004 Acute Graft vs Host Disease CYP-001 Kidney Transplantation CYP-001 Ongoing Results: Q2 CY 2026 Results: Q2 CY 2026 Cohort 1 Results: Q4 CY 2025 US$600m1 US$5.9bn4 Ongoing Ongoing 1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026) 2. Zion Market Research, 2019 (represents global treatment market in 2025) 3. Persistence Market Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019 * Timing of events is approximate, based on the Company’s information as at the date of this presentation,and subject to change. Timing refers to calendar years. Diabetic Foot Ulcers CYP-006TK Results Released: Dec 2024 US$9.6bn2 Complete 5 cynata.com FY 2025 Highlights 6 Diabetic Food Ulcers Kidney Transplantation cynata.com • Phase 1 trial completed – positive safety and efficacy outcomes (see next slide). • Engagement with potential partners and planning for next-stage trials continuing. FY25 Clinical Program Highlights • First patient treated at Leiden University Medical Centre (LUMC) during FY25. • First cohort (n=3) completed post FY-end, with outcome of DSMB review imminent*. • Trial aims to show MSC therapy can reduce toxic immunosuppressant use post-transplant. Osteoarthritis Acute GvHD • Phase 2 trial recruitment advanced, with 60* patients now randomised across multiple global centres. • This program remains Cynata’s lead FDA- regulated study, with Orphan Drug Designation and strong clinical validation from two Nature Medicine publications. • Advanced follow up with all 321 patients treated — one of the largest MSC trials ever run for knee osteoarthritis. • Fully externally funded and managed by the University of Sydney under an NHMRC grant, providing clinical validation and cost efficiency for Cynata. *As of 10 November 2025 7 cynata.com CYP-006TK | DFU Phase 1 Trial Results Reduction in wound size (i.e. improvement) 12w CYP-006TK safe and well-tolerated; no withdrawals due to adverse events; no suspected serious adverse reactions Primary Objective Achieved 24w Mean change in wound surface area (all wounds) 12w 24w Larger wounds measuring >200mm2 These results are highly encouraging when compared with the results achieved using current standard of care (SOC) 8 FY25 Pre-Clinical Highlights Expanding the therapeutic potential of CymerusTM cynata.com Cardiovascular (Heart Disease Model) • In an ischaemia-reperfusion model of heart disease, Cymerus MSCs encapsulated in an implantable device* improved cardiac function, reduced scar size, and decreased fibrotic tissue buildup. • Cells remained viable and active for over 12 weeks, supporting the long-term regenerative potential of Cymerus MSC therapy. Pulmonary Fibrosis (Lung Injury Model) • Cymerus MSCs reduced inflammation and fibrosis markers in a bleomycin- induced pulmonary-fibrosis model. • Findings demonstrate broad therapeutic potential of Cynata’s MSCs across inflammatory and fibrotic diseases beyond current clinical programs. Respiratory Diseases Pulmonary Fibrosis Cardiovascular Diseases Heart Failure | Heart Attack *Device supplied by Procyon Technologies, Tucson, Arizona, USA. 9 Independent Validation of Superior Properties of Cymerus MSCs Peer-reviewed Publication Results Published in Nature’s npj Regenerative Medicine (Feb 2025)1 Direct comparison showed iPSC-derived MSCs outperformed bone marrow and adipose MSCs, with: Greater consistency and potency Enhanced immune-modulating and wound-healing effects Lower batch variability and “younger” cell profile Provides strong scientific backing for Cynata’s Cymerus manufacturing advantage and ongoing clinical programs. cynata.com 1. Hodgson-Garms et al. Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing NPJ Regen Med. 2025;10(1):7 10 FY25 Regulatory & Corporate Progress Strengthening regulatory position and corporate foundations First FDA approval of an MSC-based product (Mesoblast’s Ryoncil®; for paediatric steroid-resistant acute GvHD) is a major positive milestone for the field, which does not impede Cynata’s regulatory pathway. $8.1 million capital raise completed in Dec 2024 — supports Phase 2/3 readouts and manufacturing readiness. New Scientific Advisory Board established, providing Cynata with world- leading expertise in research, technology, development, and strategy. Establishment of SMART CRC with Cynata as a core partner – a national coordinated effort that harnesses Australia’s strengths across the entire value chain with a total budget of $238M and over 60 partners spanning industry, government, healthcare, universities, and research institutes. cynata.com 11 cynata.com Our Advantage & Outlook 12 Conventional MSC Manufacturing • MSCs sourced from donated tissue (e.g. bone marrow); ongoing supply of new donors required • Requires cell isolation and extensive replication (growth) of MSCs in a lab to produce sufficient quantities • Drawbacks: donor variability, potency loss, low yield, and inconsistent quality • Limited scalability and consistency; challenges with commercial viability Our Manufacturing Advantage CymerusTM Manufacturing • Single blood donation → converted to induced pluripotent stem cells (iPSCs) • Creates a master cell bank as a tried and tested source to be used indefinitely for MSC production • Advantages: consistent, potent, scalable, and cost- effective manufacturing • One donor. One time. A truly off-the-shelf MSC platform cynata.com 13 What Our Manufacturing From scientific first to leadership in MSC medicine. Breakthrough Unlocks cynata.com 1. 2. 3. Allows Cynata to undertake clinical trials using a potent, consistent product Eliminates decades-old barrier to scalable MSC commercialisation Only Company that can produce consistent & non-variable MSCs at scale Allows healing properties of MSCs to be tested consistently in multi-billion-dollar indications 4. 14 cynata.com Upcoming Landmark Readouts Market Size Next Catalyst* US$11.6bn2 Osteoarthritis CYP-004 Acute Graft vs Host Disease CYP-001 Kidney Transplantation CYP-001 Phase 3 Results: Q2 CY26 (Efficacy & Safety) Phase 2 Results: Q2 CY26 (Safety + Efficacy) Cohort 1 Phase 1/2 Results: Q4 CY25 (Preliminary Safety) US$600m1 US$5.9bn3 Upcoming Preliminary Readouts The Next 6-9 Months Will Define Cynata Later stage results could become a strategic trigger All commercial activities referenced are potential future options only. No agreements have been made. Licensing / Partnering • Positive Phase 2 & 3 results can trigger regional or indication-specific deals • All our indications are attractive licensing targets with clear market needs • Partnership revenue can help fund future trials without equity dilution M&A Potential • Compelling data + scalable platform = highly strategic assets • Strong potential for synergies with other MSC technologies in the market Joint Development / Pharma Alliances • Shared risk models appeal to global pharma with aligned pipelines • Allows Cynata to enter new markets with global reach and local execution 1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026) 2. Persistence Market Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 3. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019 15 But I must explain to you how this Service Three But I must explain to you how this Service One But I must explain to you how this Service Five Solves the MSC manufacturing bottleneck with single- donor scalability First mover with no direct peers - only clinical grade iPSC MSC platform at scale Lead asset backed by FDA Orphan Drug designation and solid IP protection Landmark Phase 2 & 3 readouts expected this financial year Fully funded through major clinical milestones Trades at a discount to biotech peers despite sector leadership Investment The Case Why Cynata? Why Now? cynata.com 16 Thank You. Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia +61 (03) 7067 6940 investors@cynata.com www.cynata.com